174 related articles for article (PubMed ID: 33715247)
1. JARID1-targeted histone H3 demethylase inhibitors exhibit anti-proliferative activity and overcome cisplatin resistance in canine oral melanoma cell lines.
Tobin SJ; Chang H; Kent MS; Davies AE
Vet Comp Oncol; 2021 Sep; 19(3):518-528. PubMed ID: 33715247
[TBL] [Abstract][Full Text] [Related]
2. JARID1 Histone Demethylases: Emerging Targets in Cancer.
Harmeyer KM; Facompre ND; Herlyn M; Basu D
Trends Cancer; 2017 Oct; 3(10):713-725. PubMed ID: 28958389
[TBL] [Abstract][Full Text] [Related]
3. Identification of small molecule inhibitors of Jumonji AT-rich interactive domain 1B (JARID1B) histone demethylase by a sensitive high throughput screen.
Sayegh J; Cao J; Zou MR; Morales A; Blair LP; Norcia M; Hoyer D; Tackett AJ; Merkel JS; Yan Q
J Biol Chem; 2013 Mar; 288(13):9408-17. PubMed ID: 23408432
[TBL] [Abstract][Full Text] [Related]
4. Small Molecule Inhibitors of KDM5 Histone Demethylases Increase the Radiosensitivity of Breast Cancer Cells Overexpressing JARID1B.
Pippa S; Mannironi C; Licursi V; Bombardi L; Colotti G; Cundari E; Mollica A; Coluccia A; Naccarato V; La Regina G; Silvestri R; Negri R
Molecules; 2019 May; 24(9):. PubMed ID: 31060229
[No Abstract] [Full Text] [Related]
5. JARID1B deletion induced apoptosis in Jeko-1 and HL-60 cell lines.
Su H; Ma X; Huang Y; Han H; Zou Y; Huang W
Int J Clin Exp Pathol; 2015; 8(1):171-83. PubMed ID: 25755704
[TBL] [Abstract][Full Text] [Related]
6. Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells.
Roesch A; Vultur A; Bogeski I; Wang H; Zimmermann KM; Speicher D; Körbel C; Laschke MW; Gimotty PA; Philipp SE; Krause E; Pätzold S; Villanueva J; Krepler C; Fukunaga-Kalabis M; Hoth M; Bastian BC; Vogt T; Herlyn M
Cancer Cell; 2013 Jun; 23(6):811-25. PubMed ID: 23764003
[TBL] [Abstract][Full Text] [Related]
7. Pevonedistat targeted therapy inhibits canine melanoma cell growth through induction of DNA re-replication and senescence.
Wood EA; Lu Z; Jia S; Assumpção ALFV; Van Hesteren MA; Huelsmeyer MK; Vail DM; Pan X
Vet Comp Oncol; 2020 Sep; 18(3):269-280. PubMed ID: 31665821
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15.
Duan L; Perez RE; Calhoun S; Maki CG
Cancer Biol Ther; 2022 Dec; 23(1):65-75. PubMed ID: 35100078
[TBL] [Abstract][Full Text] [Related]
9. The KDM5 family of histone demethylases as targets in oncology drug discovery.
Rasmussen PB; Staller P
Epigenomics; 2014 Jun; 6(3):277-86. PubMed ID: 25111482
[TBL] [Abstract][Full Text] [Related]
10. Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma.
Yu Y; Schleich K; Yue B; Ji S; Lohneis P; Kemper K; Silvis MR; Qutob N; van Rooijen E; Werner-Klein M; Li L; Dhawan D; Meierjohann S; Reimann M; Elkahloun A; Treitschke S; Dörken B; Speck C; Mallette FA; Zon LI; Holmen SL; Peeper DS; Samuels Y; Schmitt CA; Lee S
Cancer Cell; 2018 Feb; 33(2):322-336.e8. PubMed ID: 29438700
[TBL] [Abstract][Full Text] [Related]
11. Histone Demethylase KDM7A Regulates Androgen Receptor Activity, and Its Chemical Inhibitor TC-E 5002 Overcomes Cisplatin-Resistance in Bladder Cancer Cells.
Lee KH; Kim BC; Jeong SH; Jeong CW; Ku JH; Kim HH; Kwak C
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32781788
[TBL] [Abstract][Full Text] [Related]
12. Histone demethylase JARID1B/KDM5B promotes aggressiveness of non-small cell lung cancer and serves as a good prognostic predictor.
Kuo KT; Huang WC; Bamodu OA; Lee WH; Wang CH; Hsiao M; Wang LS; Yeh CT
Clin Epigenetics; 2018 Aug; 10(1):107. PubMed ID: 30092824
[TBL] [Abstract][Full Text] [Related]
13. Targeting epigenetic regulators to overcome drug resistance in cancers.
Wang N; Ma T; Yu B
Signal Transduct Target Ther; 2023 Feb; 8(1):69. PubMed ID: 36797239
[TBL] [Abstract][Full Text] [Related]
14. Elevated H3K27me3 levels sensitize osteosarcoma to cisplatin.
He C; Sun J; Liu C; Jiang Y; Hao Y
Clin Epigenetics; 2019 Jan; 11(1):8. PubMed ID: 30651137
[TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of MAPK and PI3K/AKT pathway activation and inhibition in human and canine melanoma.
Fowles JS; Denton CL; Gustafson DL
Vet Comp Oncol; 2015 Sep; 13(3):288-304. PubMed ID: 23745794
[TBL] [Abstract][Full Text] [Related]
16. KDM5B demethylates H3K4 to recruit XRCC1 and promote chemoresistance.
Xu W; Zhou B; Zhao X; Zhu L; Xu J; Jiang Z; Chen D; Wei Q; Han M; Feng L; Wang S; Wang X; Zhou J; Jin H
Int J Biol Sci; 2018; 14(9):1122-1132. PubMed ID: 29989047
[TBL] [Abstract][Full Text] [Related]
17. KdmB, a Jumonji Histone H3 Demethylase, Regulates Genome-Wide H3K4 Trimethylation and Is Required for Normal Induction of Secondary Metabolism in Aspergillus nidulans.
Gacek-Matthews A; Berger H; Sasaki T; Wittstein K; Gruber C; Lewis ZA; Strauss J
PLoS Genet; 2016 Aug; 12(8):e1006222. PubMed ID: 27548260
[TBL] [Abstract][Full Text] [Related]
18. Structure of the Arabidopsis JMJ14-H3K4me3 Complex Provides Insight into the Substrate Specificity of KDM5 Subfamily Histone Demethylases.
Yang Z; Qiu Q; Chen W; Jia B; Chen X; Hu H; He K; Deng X; Li S; Tao WA; Cao X; Du J
Plant Cell; 2018 Jan; 30(1):167-177. PubMed ID: 29233856
[TBL] [Abstract][Full Text] [Related]
19. Studies of H3K4me3 demethylation by KDM5B/Jarid1B/PLU1 reveals strong substrate recognition in vitro and identifies 2,4-pyridine-dicarboxylic acid as an in vitro and in cell inhibitor.
Kristensen LH; Nielsen AL; Helgstrand C; Lees M; Cloos P; Kastrup JS; Helin K; Olsen L; Gajhede M
FEBS J; 2012 Jun; 279(11):1905-14. PubMed ID: 22420752
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effects of celecoxib in COX-2 expressing and non-expressing canine melanoma cell lines.
Seo KW; Coh YR; Rebhun RB; Ahn JO; Han SM; Lee HW; Youn HY
Res Vet Sci; 2014 Jun; 96(3):482-6. PubMed ID: 24656746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
